2025-12-18

A global leader in analytical instrumentation, Shimadzu has been integrating AI-driven technologies into its chromatography and mass spectrometry platforms to enhance efficiency, data quality and regulatory compliance in pharmaceutical and research laboratories.

Shimadzu’s analytical portfolio broadly comprises chromatography-based systems, primarily focused on separation, and mass spectrometry systems used for compound identification, screening, and advanced analytical studies. In recent years, the company has introduced AI-enabled solutions across both platforms to improve productivity and significantly reduce manual intervention.

A key development is the introduction of “analytical intelligence” across Shimadzu’s chromatography systems. This technology enables instruments to monitor their own performance, diagnose issues in real time, and automatically take corrective actions during data acquisition—without requiring user intervention. By embedding expert-level decision-making into the system, analytical intelligence ensures high-quality, reproducible data regardless of the operator’s experience. As a result, laboratory analysts can spend less time on routine troubleshooting and more time on documentation, compliance, and other critical tasks.

Another notable software advancement is LabSolutions MD, a method development tool designed to automate the traditionally time-consuming process of optimising chromatographic conditions. Using AI-based algorithms for gradient optimisation, peak tracking, and automated data processing, the software supports Quality by Design (QbD) methodologies that are increasingly emphasised by regulatory authorities. This enables laboratories to develop robust, reproducible, and compliant analytical methods while minimising manual effort.

In the mass spectrometry segment, Shimadzu has recently introduced the RX series triple quadrupole LC-MS, designed for high-throughput quantitative analysis. The platform addresses current pharmaceutical challenges such as nitrosamine testing and Extractables and Leachables (E&L) analysis. With a focus on ruggedness, robustness, and high sensitivity, the RX series allows laboratories to process large sample volumes with minimal downtime.

AI integration also extends to mass spectrometry data processing through Peak Intelligence, an advanced software algorithm that enables parameter-less integration. By leveraging historically curated, expert-analysed datasets, the software delivers consistent and refined results, reducing reliance on highly specialised users and improving overall data reliability.

Regarding the cost of AI-enabled instrumentation, Shimadzu representatives shared that while these advanced features come at an additional investment, pharmaceutical customers increasingly prioritise data clarity, compliance and operational efficiency and in this context, investment in advanced analytical technologies is viewed as essential to ensuring accurate, reliable and regulatory-ready results.

Shimadzu’s market strength is built on its 150-year legacy of innovation. The company operates across diverse domains, including analytical and measuring instruments, medical diagnostics, scientific and testing equipment, and aerospace systems. Its commitment to scientific excellence is exemplified by the 2002 Nobel Prize in Chemistry awarded to Shimadzu scientist Koichi Tanaka for his pioneering work on MALDI technology.

By continuing to integrate AI, refine software capabilities, and enhance instrument performance, Shimadzu remains focused on helping laboratories meet evolving regulatory demands and scientific challenges—while improving efficiency, accuracy and analytical confidence.